Medline (MDLN) Cash & Equivalents (2024 - 2026)

Medline (MDLN) has reported Cash & Equivalents for 3 consecutive years, with $2.2 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents changed N/A year-over-year to $2.2 billion; the TTM figure through Mar 2026 stood at $2.2 billion (changed N/A YoY), while the FY2025 annual figure was $1.9 billion, up 874.37% from the prior year.
• Cash & Equivalents rose to $2.2 billion in Q1 2026 per MDLN's latest filing, from $1.9 billion in the prior quarter.
• Across five years, Cash & Equivalents topped out at $2.2 billion in Q1 2026 and bottomed at $199.0 million in Q4 2024.
• Historically, Cash & Equivalents has averaged $1.5 billion across 3 years, with a median of $1.9 billion in 2025.
• On a YoY basis, Cash & Equivalents climbed as much as 874.37% in 2025 and fell as far as 874.37% in 2025.
• Medline's Cash & Equivalents stood at $199.0 million in 2024, then jumped by 874.37% to $1.9 billion in 2025, then climbed by 15.32% to $2.2 billion in 2026.
• Business Quant data shows MDLN's Cash & Equivalents at $2.2 billion in Q1 2026, $1.9 billion in Q4 2025, and $199.0 million in Q4 2024.